|
US7090843B1
(en)
†
|
2000-11-28 |
2006-08-15 |
Seattle Genetics, Inc. |
Recombinant anti-CD30 antibodies and uses thereof
|
|
US20040018194A1
(en)
*
|
2000-11-28 |
2004-01-29 |
Francisco Joseph A. |
Recombinant anti-CD30 antibodies and uses thereof
|
|
US20110313230A1
(en)
|
2001-05-11 |
2011-12-22 |
Terrance Grant Johns |
Specific binding proteins and uses thereof
|
|
EP1482972A4
(en)
*
|
2001-11-20 |
2005-11-23 |
Seattle Genetics Inc |
TREATMENT OF IMMUNOLOGICAL DISORDERS USING ANTI-CD30 ANTIBODIES
|
|
WO2003055527A2
(en)
*
|
2002-01-03 |
2003-07-10 |
Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw |
Immunoconjugates useful for treatment of tumours
|
|
CA2471702C
(en)
*
|
2002-01-09 |
2013-03-19 |
Medarex, Inc. |
Human monoclonal antibodies against cd30
|
|
US20070148171A1
(en)
*
|
2002-09-27 |
2007-06-28 |
Xencor, Inc. |
Optimized anti-CD30 antibodies
|
|
ES2544527T3
(es)
*
|
2002-07-31 |
2015-09-01 |
Seattle Genetics, Inc. |
Conjugados de fármacos y su uso para tratar el cáncer, una enfermedad autoinmune o una enfermedad infecciosa
|
|
CN103394083B
(zh)
|
2003-11-06 |
2017-07-18 |
西雅图基因公司 |
能够与配体偶联的单甲基缬氨酸化合物
|
|
EP1802345A2
(en)
|
2004-10-01 |
2007-07-04 |
Medarex, Inc. |
Methods of treating cd30 positive lymphomas
|
|
NZ560209A
(en)
|
2005-02-18 |
2009-04-30 |
Medarex Inc |
Monoclonal antibodies against CD30 lacking in fucosyl residues
|
|
EP1951757B1
(en)
|
2005-10-06 |
2014-05-14 |
Xencor, Inc. |
Optimized anti-cd30 antibodies
|
|
US8257706B2
(en)
*
|
2006-08-25 |
2012-09-04 |
Seattle Genetics, Inc. |
CD30 binding agents and uses thereof
|
|
PL2176296T3
(pl)
|
2007-07-16 |
2012-07-31 |
Genentech Inc |
Przeciwciała anty-CD79B i immunokoniugaty i sposoby stosowania
|
|
CN101802013B
(zh)
|
2007-07-16 |
2014-07-02 |
健泰科生物技术公司 |
人源化抗cd79b抗体和免疫偶联物及使用方法
|
|
US8865875B2
(en)
|
2007-08-22 |
2014-10-21 |
Medarex, L.L.C. |
Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions
|
|
MX2010003977A
(es)
*
|
2007-10-12 |
2010-04-30 |
Seattle Genetics Inc |
Terapia de combinacion con conjugados de anticuerpo-farmaco.
|
|
SI2247620T1
(sl)
|
2008-01-31 |
2016-09-30 |
Genentech, Inc. |
Protitelesa proti CD79b in imunokonjugati in postopki za uporabo
|
|
WO2010027513A2
(en)
|
2008-09-08 |
2010-03-11 |
Psma Development Company, Llc |
Methods for killing psma-expressing, taxane-resistant cancer cells
|
|
CA3159253A1
(en)
|
2009-01-09 |
2010-07-15 |
Seagen Inc. |
Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates
|
|
KR101224468B1
(ko)
*
|
2009-05-20 |
2013-01-23 |
주식회사 파멥신 |
신규한 형태의 이중표적항체 및 그 용도
|
|
US20110076232A1
(en)
|
2009-09-29 |
2011-03-31 |
Ludwig Institute For Cancer Research |
Specific binding proteins and uses thereof
|
|
CN103561759B
(zh)
|
2010-10-22 |
2016-10-12 |
西雅图遗传学公司 |
以奥里斯他汀(AURISTATIN)为主的抗体药物结合物与PI3K-AKT mTOR路径抑制剂之间的协同作用
|
|
US9764038B2
(en)
|
2011-12-23 |
2017-09-19 |
Innate Pharma |
Enzymatic conjugation of antibodies
|
|
CN110078818B
(zh)
*
|
2012-04-27 |
2023-12-29 |
诺和诺德股份有限公司 |
人cd30配体抗原结合蛋白
|
|
WO2014009426A2
(en)
|
2012-07-13 |
2014-01-16 |
Innate Pharma |
Screening of conjugated antibodies
|
|
US10195288B2
(en)
|
2012-10-11 |
2019-02-05 |
Daiichi Sankyo Company, Limited |
Antibody-drug conjugate
|
|
EP2910573B1
(en)
|
2012-10-19 |
2020-02-19 |
Daiichi Sankyo Company, Limited |
Antibody-drug conjugate produced by binding through linker having hydrophilic structure
|
|
WO2014072482A1
(en)
|
2012-11-09 |
2014-05-15 |
Innate Pharma |
Recognition tags for tgase-mediated conjugation
|
|
CA2891280C
(en)
|
2012-11-24 |
2018-03-20 |
Hangzhou Dac Biotech Co., Ltd. |
Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
|
|
WO2014089177A2
(en)
|
2012-12-04 |
2014-06-12 |
Massachusetts Institute Of Technology |
Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
|
|
AU2013364065B2
(en)
|
2012-12-21 |
2018-10-04 |
Altrubio Inc. |
Hydrophilic self-immolative linkers and conjugates thereof
|
|
EP2968582B1
(en)
|
2013-03-15 |
2020-07-01 |
Innate Pharma |
Solid phase tgase-mediated conjugation of antibodies
|
|
US20140286969A1
(en)
|
2013-03-15 |
2014-09-25 |
Abbvie Inc. |
Anti-egfr antibody drug conjugate formulations
|
|
AU2014240012A1
(en)
|
2013-03-15 |
2015-09-24 |
Abbvie Inc. |
Antibody drug conjugate (ADC) purification
|
|
MX2015014181A
(es)
|
2013-04-09 |
2016-05-24 |
Boston Biomedical Inc |
2-acetilnafto [2,3-b]furano -4,9-diona para uso en el tratamiento del cáncer.
|
|
EP3010547B1
(en)
|
2013-06-20 |
2021-04-21 |
Innate Pharma |
Enzymatic conjugation of polypeptides
|
|
JP6744212B2
(ja)
|
2013-06-21 |
2020-08-19 |
イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. |
ポリペプチドの酵素的結合
|
|
KR102645430B1
(ko)
|
2013-10-15 |
2024-03-11 |
씨젠 인크. |
개선된 리간드-약물 컨쥬게이트 약물동력학을 위한 peg화된 약물-링커
|
|
JP2017510548A
(ja)
|
2014-01-29 |
2017-04-13 |
シャンハイ ヘンルイ ファーマスーティカル カンパニー リミテッドShanghai Hengrui Pharmaceutical Co., Ltd. |
リガンド‐細胞傷害性薬物抱合体、その製造方法、およびその用途
|
|
WO2015127685A1
(en)
|
2014-02-28 |
2015-09-03 |
Hangzhou Dac Biotech Co., Ltd |
Charged linkers and their uses for conjugation
|
|
WO2015142675A2
(en)
|
2014-03-15 |
2015-09-24 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor
|
|
RU2017101662A
(ru)
|
2014-06-20 |
2018-07-23 |
Биоэллаенс К.В. |
Конъюгаты антитела против фолатного рецептора альфа (fra) c лекарственным средством и способы их применения
|
|
EP3682904A1
(en)
|
2014-06-30 |
2020-07-22 |
Glykos Finland Oy |
Saccharide derivative of a toxic payload and antibody conjugates thereof
|
|
JP2017528433A
(ja)
|
2014-07-21 |
2017-09-28 |
ノバルティス アーゲー |
低い免疫増強用量のmTOR阻害剤とCARの組み合わせ
|
|
CA2979671C
(en)
|
2014-09-23 |
2020-03-10 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates
|
|
WO2016126608A1
(en)
|
2015-02-02 |
2016-08-11 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
EP3286211A1
(en)
|
2015-04-23 |
2018-02-28 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
EP3303373B1
(en)
|
2015-05-30 |
2020-04-08 |
Molecular Templates, Inc. |
De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
|
|
WO2016196935A1
(en)
|
2015-06-03 |
2016-12-08 |
Boston Biomedical, Inc. |
Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer
|
|
AU2015242210A1
(en)
|
2015-06-15 |
2017-12-07 |
Hangzhou Dac Biotech Co., Ltd |
Hydrophilic linkers for conjugation
|
|
EP3319936B1
(en)
|
2015-07-12 |
2025-12-17 |
Hangzhou Dac Biotech Co., Ltd. |
Bridge linkers for conjugation of cell-binding molecules
|
|
US9839687B2
(en)
|
2015-07-15 |
2017-12-12 |
Suzhou M-Conj Biotech Co., Ltd. |
Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
|
|
EP3331913A1
(en)
|
2015-08-07 |
2018-06-13 |
Novartis AG |
Treatment of cancer using chimeric cd3 receptor proteins
|
|
SI3380620T1
(sl)
|
2015-11-23 |
2024-09-30 |
Novartis Ag |
Optimizirani lentivirusni prenosni vektorji in njihove uporabe
|
|
AU2016382512A1
(en)
|
2015-12-30 |
2018-07-12 |
Novartis Ag |
Immune effector cell therapies with enhanced efficacy
|
|
RU2766000C2
(ru)
|
2016-01-08 |
2022-02-07 |
АльтруБио Инк. |
Четырехвалентные антитела к psgl-1 и их применения
|
|
WO2017165683A1
(en)
|
2016-03-23 |
2017-09-28 |
Novartis Ag |
Cell secreted minibodies and uses thereof
|
|
KR20180134351A
(ko)
|
2016-03-25 |
2018-12-18 |
시애틀 지네틱스, 인크. |
페길화된 약물-링커 및 그의 중간체의 제조를 위한 공정
|
|
WO2017197045A1
(en)
|
2016-05-11 |
2017-11-16 |
Movassaghi Mohammad |
Convergent and enantioselective total synthesis of communesin analogs
|
|
JP7523907B2
(ja)
|
2016-11-14 |
2024-07-29 |
武田薬品工業株式会社 |
非成人のヒトに対する抗cd30抗体-薬物コンジュゲートの投与
|
|
JP7138350B2
(ja)
|
2016-11-14 |
2022-09-16 |
ハンジョウ ディーエーシー バイオテック シーオー.,エルティディ. |
共役連結体、該連結体を含有する細胞結合分子-薬物共役体、並びに該共役体及び連結体の使用及び製造方法
|
|
US11299469B2
(en)
|
2016-11-29 |
2022-04-12 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Naphthofuran derivatives, preparation, and methods of use thereof
|
|
WO2018111340A1
(en)
|
2016-12-16 |
2018-06-21 |
Novartis Ag |
Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
|
|
CN106854245A
(zh)
*
|
2016-12-28 |
2017-06-16 |
无锡傲锐东源生物科技有限公司 |
抗cd30蛋白单克隆抗体及其用途
|
|
US11535662B2
(en)
|
2017-01-26 |
2022-12-27 |
Novartis Ag |
CD28 compositions and methods for chimeric antigen receptor therapy
|
|
WO2018144535A1
(en)
|
2017-01-31 |
2018-08-09 |
Novartis Ag |
Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
|
|
EP3589647A1
(en)
|
2017-02-28 |
2020-01-08 |
Novartis AG |
Shp inhibitor compositions and uses for chimeric antigen receptor therapy
|
|
WO2018158716A1
(en)
|
2017-03-02 |
2018-09-07 |
Cadila Healthcare Limited |
Novel protein drug conjugate formulation
|
|
JP7527787B2
(ja)
|
2017-03-24 |
2024-08-05 |
シージェン インコーポレイテッド |
グルクロニド薬物-リンカーの調製のためのプロセスおよびその中間体
|
|
US10646464B2
(en)
|
2017-05-17 |
2020-05-12 |
Boston Biomedical, Inc. |
Methods for treating cancer
|
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
|
CN111526893A
(zh)
|
2017-10-11 |
2020-08-11 |
西雅图知耐特公司 |
减少抗cd30抗体药物偶联物疗法的副作用的方法
|
|
US10640508B2
(en)
|
2017-10-13 |
2020-05-05 |
Massachusetts Institute Of Technology |
Diazene directed modular synthesis of compounds with quaternary carbon centers
|
|
MX2020004229A
(es)
|
2017-10-25 |
2020-07-22 |
Novartis Ag |
Metodos de produccion de celulas que expresan receptores antigenicos quimericos.
|
|
WO2019081983A1
(en)
|
2017-10-25 |
2019-05-02 |
Novartis Ag |
CD32B TARGETING ANTIBODIES AND METHODS OF USE
|
|
WO2019089798A1
(en)
|
2017-10-31 |
2019-05-09 |
Novartis Ag |
Anti-car compositions and methods
|
|
US20220226439A1
(en)
|
2017-11-01 |
2022-07-21 |
Seagen Inc. |
Methods of reducing side effects of anti-cd30 antibody drug conjugate therapy
|
|
CN117126279A
(zh)
|
2018-03-20 |
2023-11-28 |
鸿运华宁(杭州)生物医药有限公司 |
Gipr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用
|
|
WO2019183438A1
(en)
|
2018-03-23 |
2019-09-26 |
Seattle Genetics, Inc. |
Use of antibody drug conjugates comprising tubulin disrupting agents to treat solid tumor
|
|
EP3784351A1
(en)
|
2018-04-27 |
2021-03-03 |
Novartis AG |
Car t cell therapies with enhanced efficacy
|
|
EP3788369A1
(en)
|
2018-05-01 |
2021-03-10 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
|
EP3801769A1
(en)
|
2018-05-25 |
2021-04-14 |
Novartis AG |
Combination therapy with chimeric antigen receptor (car) therapies
|
|
TW202519270A
(zh)
|
2018-06-07 |
2025-05-16 |
美商思進公司 |
喜樹鹼結合物
|
|
US20210123075A1
(en)
|
2018-06-08 |
2021-04-29 |
Novartis Ag |
Compositions and methods for immunooncology
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
EP3856777A1
(en)
|
2018-09-24 |
2021-08-04 |
The Medical College of Wisconsin, Inc. |
Anti-cd30 antibodies and methods of use
|
|
KR20210066833A
(ko)
|
2018-09-26 |
2021-06-07 |
지앙수 헨그루이 메디슨 컴퍼니 리미티드 |
엑사테칸 유사체의 리간드-약물 접합체, 이를 위한 제조 방법, 및 이의 적용
|
|
MX2021003734A
(es)
|
2018-10-01 |
2021-07-16 |
Seagen Inc |
Métodos de tratamiento del linfoma de linfocitos t periférico mediante terapia con conjugado fármaco-anticuerpo anti-cd30.
|
|
EP3883610A4
(en)
|
2018-11-20 |
2022-11-02 |
Cornell University |
MACROCYCLIC COMPLEXES OF RADIONUCLIDES AND THEIR USE IN CANCER RADIATION THERAPY
|
|
CA3123511A1
(en)
|
2018-12-20 |
2020-06-25 |
Novartis Ag |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
EP3924054B1
(en)
|
2019-02-15 |
2025-04-02 |
Novartis AG |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
MX2021009764A
(es)
|
2019-02-15 |
2021-09-08 |
Novartis Ag |
Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona sustituidos y usos de los mismos.
|
|
WO2020210719A1
(en)
|
2019-04-10 |
2020-10-15 |
Elevatebio Management, Inc. |
Flt3-specific chimeric antigen receptors and methods of using the same
|
|
JP7467610B2
(ja)
|
2019-09-18 |
2024-04-15 |
バイリ-バイオ(チェンドゥ)ファーマスーティカル シーオー.,エルティーディー. |
カンプトテシン誘導体及びその複合体
|
|
EP4034154A1
(en)
|
2019-09-25 |
2022-08-03 |
Seagen Inc. |
Combination anti-cd30 adc, anti-pd-1 and chemotherapeutic for treatment of hematopoietic cancers
|
|
JP2022550851A
(ja)
|
2019-10-04 |
2022-12-05 |
シージェン インコーポレイテッド |
カンプトテシンペプチドコンジュゲート
|
|
WO2021067820A1
(en)
|
2019-10-04 |
2021-04-08 |
Seagen Inc. |
Formulation of antibody-drug conjugate
|
|
CA3160151A1
(en)
|
2019-11-04 |
2021-05-14 |
Seagen Inc. |
Anti-cd30 antibody-drug conjugates and their use for the treatment of hiv infection
|
|
CN115175937A
(zh)
|
2019-12-20 |
2022-10-11 |
诺华股份有限公司 |
用于治疗骨髓纤维化和骨髓增生异常综合征的抗TIM-3抗体MBG453和抗TGF-β抗体NIS793与或不与地西他滨或抗PD-1抗体斯巴达珠单抗的组合
|
|
CA3168654A1
(en)
|
2020-01-22 |
2021-07-29 |
Shanghai Senhui Medicine Co., Ltd. |
Drug conjugate of eribulin derivative, preparation method therefor and application thereof in medicine
|
|
EP4096713A1
(en)
|
2020-01-31 |
2022-12-07 |
Seagen Inc. |
Anti-cd30 antibody-drug conjugates and their use for the treatment of non-hodgkin lymphoma
|
|
JP7730836B2
(ja)
|
2020-03-25 |
2025-08-28 |
江蘇恒瑞医薬股▲ふん▼有限公司 |
抗体薬物複合体の調製方法
|
|
JP7689979B2
(ja)
|
2020-03-25 |
2025-06-09 |
江蘇恒瑞医薬股▲ふん▼有限公司 |
抗体薬物複合体を含む医薬組成物及びその使用
|
|
IL297167A
(en)
|
2020-04-10 |
2022-12-01 |
Seagen Inc |
Charging variant connectors
|
|
WO2021231568A1
(en)
|
2020-05-13 |
2021-11-18 |
Seagen Inc. |
Methods of treating cancer using a combination of anti-cd30 antibody-drug conjugates
|
|
US20230332104A1
(en)
|
2020-06-11 |
2023-10-19 |
Novartis Ag |
Zbtb32 inhibitors and uses thereof
|
|
CA3182346A1
(en)
|
2020-06-23 |
2021-12-30 |
Novartis Ag |
Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
US20230271940A1
(en)
|
2020-08-03 |
2023-08-31 |
Novartis Ag |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
KR20230133331A
(ko)
|
2021-01-15 |
2023-09-19 |
씨젠 인크. |
면역조절 항체-약물 컨쥬게이트
|
|
EP4308170A1
(en)
|
2021-03-18 |
2024-01-24 |
Seagen Inc. |
Selective drug release from internalized conjugates of biologically active compounds
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
IL307548A
(en)
|
2021-04-20 |
2023-12-01 |
Seagen Inc |
Modulation of antibody-dependent cellular cytotoxicity
|
|
JP2024515793A
(ja)
|
2021-04-27 |
2024-04-10 |
ノバルティス アーゲー |
ウイルスベクター生産システム
|
|
JP2024520562A
(ja)
|
2021-05-28 |
2024-05-24 |
シージェン インコーポレイテッド |
アントラサイクリン抗体コンジュゲート
|
|
CA3236735A1
(en)
|
2021-10-29 |
2023-05-04 |
Seagen Inc. |
Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-cd30 antibody-drug conjugate
|
|
CN117980327A
(zh)
|
2021-11-03 |
2024-05-03 |
杭州多禧生物科技有限公司 |
抗体的特异性偶联
|
|
CN114891101B
(zh)
*
|
2021-12-02 |
2023-06-16 |
吉林省农业科学院 |
一种牛肌肉生长抑制素蛋白单克隆抗体及其应用
|
|
KR20250004952A
(ko)
|
2022-03-17 |
2025-01-08 |
씨젠 인크. |
캄프토테신 접합체
|
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
|
WO2023215740A1
(en)
|
2022-05-06 |
2023-11-09 |
Seagen Inc. |
Immunomodulatory antibody-drug conjugates
|
|
AU2023365454A1
(en)
|
2022-10-18 |
2025-04-03 |
Meiji Seika Pharma Co., Ltd. |
Therapeutic agent for t cell malignancies
|
|
WO2024089639A1
(en)
|
2022-10-26 |
2024-05-02 |
Novartis Ag |
Lentiviral formulations
|
|
WO2024129756A1
(en)
|
2022-12-13 |
2024-06-20 |
Seagen Inc. |
Site-specific engineered cysteine antibody drug conjugates
|
|
TW202500193A
(zh)
|
2023-03-22 |
2025-01-01 |
美商信立泰生物醫藥公司 |
抗5t4抗原結合結構域、抗體-藥物共軛體及彼等之使用方法
|
|
CN120981456A
(zh)
|
2023-05-24 |
2025-11-18 |
金橘生物科技公司 |
杂环化合物及其用途
|
|
WO2025090774A1
(en)
|
2023-10-24 |
2025-05-01 |
Seagen Inc. |
Chemotherapeutic compounds and methods of use
|
|
WO2025096626A1
(en)
|
2023-10-31 |
2025-05-08 |
Seagen Inc. |
Methods of treating cancers using anti-cd30 antibody-drug conjugates
|
|
WO2025149947A1
(en)
|
2024-01-12 |
2025-07-17 |
Seagen Inc. |
Antibody-drug conjugates
|
|
WO2025169056A1
(en)
|
2024-02-06 |
2025-08-14 |
Seagen Inc. |
Methods of treating cancers using anti-cd30 antibody-drug conjugates
|
|
CN119331093B
(zh)
*
|
2024-11-04 |
2025-07-11 |
武汉伊莱瑞特生物科技股份有限公司 |
一种抗CD30的兔源Fab抗体及其制备方法和应用
|